Press "Enter" to skip to content

Lupin gets 4 observations from USFDA after closure of pharmacovigilance inspection

Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the post-marketing adverse drug experience (PADE) inspection, indicating successful closure of the inspection, the filing added.

Original source: https://health.economictimes.indiatimes.com/news/pharma/lupin-gets-4-observations-from-usfda-after-closure-of-pharmacovigilance-inspection/69321741?utm_source=RSS&utm_medium=ETRSS

Also Read:   Delhi govt makes first list of corona warriors for vaccine